Cargando…
Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence
Tenofovir alafenamide (TAF), a novel prodrug of tenofovir was developed to deliver enhanced antiviral potency and reduced systemic toxicities by more efficient intracellular delivery of the active metabolite tenofovir disphosphate than tenofovir disoproxil fumarate (TDF). In two randomized, double-b...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6048601/ https://www.ncbi.nlm.nih.gov/pubmed/30034532 http://dx.doi.org/10.1177/1756284818786108 |